Kaibo Feng1, Raundi E Quevedo1, Jeffrey T Kohrt2, Martins S Oderinde3, Usa Reilly2, M Christina White4. 1. Department of Chemistry, Roger Adams Laboratory, University of Illinois, Urbana, IL, USA. 2. Pfizer Worldwide Research and Development, Groton Laboratories, Groton, CT, USA. 3. Research and Development, Bristol-Myers Squibb Company, Lawrenceville, NJ, USA. 4. Department of Chemistry, Roger Adams Laboratory, University of Illinois, Urbana, IL, USA. mcwhite7@illinois.edu.
Abstract
Frequently referred to as the 'magic methyl effect', the installation of methyl groups-especially adjacent (α) to heteroatoms-has been shown to dramatically increase the potency of biologically active molecules1-3. However, existing methylation methods show limited scope and have not been demonstrated in complex settings1. Here we report a regioselective and chemoselective oxidative C(sp3)-H methylation method that is compatible with late-stage functionalization of drug scaffolds and natural products. This combines a highly site-selective and chemoselective C-H hydroxylation with a mild, functional-group-tolerant methylation. Using a small-molecule manganese catalyst, Mn(CF3PDP), at low loading (at a substrate/catalyst ratio of 200) affords targeted C-H hydroxylation on heterocyclic cores, while preserving electron-neutral and electron-rich aryls. Fluorine- or Lewis-acid-assisted formation of reactive iminium or oxonium intermediates enables the use of a mildly nucleophilic organoaluminium methylating reagent that preserves other electrophilic functionalities on the substrate. We show this late-stage C(sp3)-H methylation on 41 substrates housing 16 different medicinally important cores that include electron-rich aryls, heterocycles, carbonyls and amines. Eighteen pharmacologically relevant molecules with competing sites-including drugs (for example, tedizolid) and natural products-are methylated site-selectively at the most electron rich, least sterically hindered position. We demonstrate the syntheses of two magic methyl substrates-an inverse agonist for the nuclear receptor RORc and an antagonist of the sphingosine-1-phosphate receptor-1-via late-stage methylation from the drug or its advanced precursor. We also show a remote methylation of the B-ring carbocycle of an abiraterone analogue. The ability to methylate such complex molecules at late stages will reduce synthetic effort and thereby expedite broader exploration of the magic methyl effect in pursuit of new small-molecule therapeutics and chemical probes.
Frequently referred to as the 'magic methyl efn class="Chemical">fect', the installation of methyl groups-especially adjacent (α) to heteroatoms-has been shown to dramatically increase the potency of biologically active molecules1-3. However, existing methylation methods show limited scope and have not been demonstrated in complex settings1. Here we report a regioselective and chemoselective oxidative C(sp3)-H methylation method that is compatible with late-stage functionalization of drug scaffolds and natural products. This combines a highly site-selective and chemoselective C-H hydroxylation with a mild, functional-group-tolerant methylation. Using a small-molecule manganese catalyst, Mn(CF3PDP), at low loading (at a substrate/catalyst ratio of 200) affords targeted C-H hydroxylation on heterocyclic cores, while preserving electron-neutral and electron-rich aryls. Fluorine- or Lewis-acid-assisted formation of reactive iminium or oxonium intermediates enables the use of a mildly nucleophilic organoaluminium methylating reagent that preserves other electrophilic functionalities on the substrate. We show this late-stage C(sp3)-H methylation on 41 substrates housing 16 different medicinally important cores that include electron-rich aryls, heterocycles, carbonyls and amines. Eighteen pharmacologically relevant molecules with competing sites-including drugs (for example, tedizolid) and natural products-are methylated site-selectively at the most electron rich, least sterically hindered position. We demonstrate the syntheses of two magic methyl substrates-an inverse agonist for the nuclear receptor RORc and an antagonist of the sphingosine-1-phosphate receptor-1-via late-stage methylation from the drug or its advanced precursor. We also show a remote methylation of the B-ring carbocycle of an abiraterone analogue. The ability to methylate such complex molecules at late stages will reduce synthetic effort and thereby expedite broader exploration of the magic methyl effect in pursuit of new small-molecule therapeutics and chemical probes.
Authors: Benjamin P Fauber; Olivier René; Yuzhong Deng; Jason DeVoss; Céline Eidenschenk; Christine Everett; Arunima Ganguli; Alberto Gobbi; Julie Hawkins; Adam R Johnson; Hank La; Justin Lesch; Peter Lockey; Maxine Norman; Wenjun Ouyang; Susan Summerhill; Harvey Wong Journal: J Med Chem Date: 2015-06-23 Impact factor: 7.446
Authors: David C Blakemore; Luis Castro; Ian Churcher; David C Rees; Andrew W Thomas; David M Wilson; Anthony Wood Journal: Nat Chem Date: 2018-03-22 Impact factor: 24.427
Authors: Jean Quancard; Birgit Bollbuck; Philipp Janser; Daniela Angst; Frédéric Berst; Peter Buehlmayer; Markus Streiff; Christian Beerli; Volker Brinkmann; Danilo Guerini; Paul A Smith; Timothy J Seabrook; Martin Traebert; Klaus Seuwen; René Hersperger; Christian Bruns; Frédéric Bassilana; Marc Bigaud Journal: Chem Biol Date: 2012-09-21